banner_2

WHY BTXATM

QUALITY GUARANTEE

BTXA™ IS DEEMED SAFE, WELL TOLERATED AND REACHED GOOD SATISFACTORY LEVELS

Efficacy and Tolerability Study of BTXA™ Treatment in Patients with Facial Wrinkles

An open-label, prospective, multicenter and multidisciplinary phase III study was carried out in Brazil. 110 patients with facial wrinkles were being studied continuously for 180 days.

 

HIGH SATISFACTORY RATE : 98% of Patients Satisfied after BTXA treatment

chart_2_5_2_1
Injection Result During the Follow Up Visits
chart_2_5_2_2

FAST ONSET - Satisfactory rate reach up to 94% in 14 days after injection

 

LONG LASTING - 50% patients maintained satisfactory result up to 6 months

Reference
  1. Costa J, Rieder C, et al. A double-blind, randomised, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007; 30:39-42
  2. Drug Safety Report-Prosigne® (Botulinum Toxin Type A), Jan 2009, Hughs. Data on file
  3. 2007 American Society of Aesthetic Plastic Surgery (ASAPS) Cosmetic Surgery National Data Bank Statistics.
  4. Talarico S, Bgatin E, Pecora CS, Ferreira LM, Orofino R, Godoy A, et al. Open-label, prospective, multicenter, multidisciplinary Phase III Study to evaluate the efficacy and tolerability of Prosigne® (Botulinum Toxin Type A) in the aesthetic treatment of the upper third of the face in patients with facial wrinkles. Data on file.
FORGOT PASSWORD
Please enter your registered email address. We will send you an email with a link to reset your password.
Submit